Track Moberg Pharma AB (publ)'s EBIT ($-24M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
The latest EBIT for MOB.ST is $-24M as of September 2026. That compares with $-320M in the prior-year period — up 92.4% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Moberg Pharma AB (publ)'s historical trend and sector peers before judging valuation or financial health.
Over the past year, MOB.ST's EBIT moved from $-320M to $-24M — a 92.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Moberg Pharma AB (publ)'s operating scale or balance-sheet position.
Against its sector companies, MOB.ST currently prints $-24M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Moberg Pharma AB (publ)'s growth, margins, and balance sheet.
A EBIT figure of $-24M for MOB.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.
After noting MOB.ST's EBIT ($-24M), review year-over-year change from $-320M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.